Targeting OX40 and OX40L for the treatment of autoimmunity and cancer

Critical Reviews in Immunology
William L Redmond, Andrew D Weinberg

Abstract

The optimal activation of naïve T cells requires TCR-mediated recognition of cognate peptide-MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28-B7 interactions are important for enhancing the initial T-cell response, other costimulatory signals are required for sustaining the response and promoting both T-cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T-cell responses. Importantly, numerous studies have highlighted the ability of OX40-specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40- and OX40L-specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40-mediated T-cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.

Citations

Sep 9, 2008·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·D SchramaJ C Becker
May 6, 2009·The Journal of Experimental Medicine·Daniel Hirschhorn-CymermanAlan N Houghton
Dec 1, 2012·Anais Brasileiros De Dermatologia·Patrícia Luciana Batista DomingosPaulo Rogério Ferreti Bonan
Jun 23, 2009·Critical Reviews in Immunology·William L RedmondAndrew D Weinberg
Jan 18, 2012·Critical Reviews in Oncogenesis·Qiang ZhangGuangchao Sui
Mar 15, 2014·Expert Opinion on Biological Therapy·Sara TomeiDavide Bedognetti
May 8, 2010·Trends in Biotechnology·Angel M CuestaLuis Alvarez-Vallina
Aug 13, 2009·European Journal of Immunology·William L RedmondAndrew D Weinberg
May 25, 2013·British Journal of Clinical Pharmacology·Chern Siang LeePeter Johnson
Oct 25, 2011·Immunological Reviews·Andrew D WeinbergBrendan D Curti
Oct 12, 2014·Cancer Letters·Haiyan ChuMeilin Wang
May 20, 2016·Clinical & Translational Immunology·Ryan MontlerAndrew Weinberg
Mar 13, 2015·Frontiers in Oncology·Stefanie N LinchWilliam L Redmond
Jul 28, 2016·Human Vaccines & Immunotherapeutics·William L Redmond, Stefanie N Linch
Jan 10, 2018·International Journal of Cancer. Journal International Du Cancer·Ngoc Pham MinhMasaji Tani
Nov 28, 2017·ESMO Open·Cinzia SolinasLaurence Buisseret
Sep 2, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Harry Z QuiAdam J Adler
Jan 19, 2018·Molecular Medicine Reports·Wei LeiJianan Huang
Jan 11, 2019·JCI Insight·Pablo Vieyra-GarciaRachael A Clark
Nov 2, 2013·Cancer Research·Brendan D CurtiAndrew D Weinberg
Jan 11, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca LeylandRoss Stewart
Jul 3, 2021·International Journal of Molecular Sciences·Karolina StachyraAnna M Czarnecka
Jul 24, 2020·Bioconjugate Chemistry·Martine DarwishCraig Blanchette

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.